FGFR2 and cholangiocarcinoma: In particular, in 3 patients with FGFR2 fusion-positive CCA treated with BGJ398, the occurrence of a secondary mutation in the FGFR2 kinase domains in one patient and multiple FGFR2 mutations in the remaining two patients were observed.